Skip to main content

Table 1 Patient sample sizes by line of treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced/metastatic breast cancer for running annual estimates during the study (n [%])

From: Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States

  Jan 12–Dec 12 Apr 12–Mar 13 Jul 12–Jun 13 Oct 12–Sep 13 Jan 13–Dec 13 Apr 13–Mar 14 Jul 13–Jun 14 Oct 13–Sep 14 Jan 14–Dec 14
Europe
 All lines n = 1483 n = 1421 n = 1364 n = 1391 n = 1435 n = 1385 n = 1272 n = 1387 n = 1640
 All first line 801 (54.0) 790 (55.6) 791 (58.0) 843 (60.6) 897 (62.5) 876 (63.2) 843 (66.3) 744 (53.6) 732 (44.6)
 No prior drug treatment (diagnosis ≤3 months)a 237 (29.6) 225 (28.5) 208 (26.3) 219 (26.0) 265 (29.5) 277 (31.6) 285 (33.8) 262 (35.2) 245 (33.5)
 No prior drug treatment (diagnosis >3 months)a 204 (25.5) 212 (26.8) 220 (27.8) 244 (28.9) 247 (27.5) 222 (25.3) 208 (24.7) 175 (23.5) 194 (26.5)
 Early recurrencea 174 (21.7) 169 (21.4) 184 (23.3) 182 (21.6) 184 (20.5) 180 (20.5) 171 (20.3) 160 (21.5) 154 (21.0)
 Late recurrencea 186 (23.2) 184 (23.3) 179 (22.6) 198 (23.5) 201 (22.4) 197 (22.5) 179 (21.2) 147 (19.8) 139 (19.0)
 Second line 436 (29.4) 417 (29.3) 376 (27.6) 351 (25.2) 347 (24.2) 333 (24.0) 273 (21.5) 471 (34.0) 696 (42.4)
 ≥Third line 246 (16.6) 214 (15.1) 197 (14.4) 197 (14.2) 191 (13.3) 176 (12.7) 156 (12.3) 172 (12.4) 212 (12.9)
United States
 All lines n = 2388 n = 2318 n = 2276 n = 2232 n = 2225 n = 2283 n = 2312 n = 2503 n = 2760
 All first line 1155 (48.4) 1185 (51.1) 1176 (51.7) 1172 (52.5) 1162 (52.2) 1169 (51.2) 1104 (47.8) 1053 (42.1) 1016 (36.8)
 No prior drug treatment (diagnosis ≤3 months)a 239 (20.7) 225 (19.0) 235 (20.0) 233 (19.9) 233 (20.1) 249 (21.3) 242 (21.9) 254 (24.1) 255 (25.1)
 No prior drug treatment (diagnosis >3 months)a 492 (42.6) 505 (42.6) 486 (41.3) 480 (41.0) 484 (41.7) 486 (41.6) 457 (41.4) 403 (38.3) 400 (39.4)
 Early recurrencea 228 (19.7) 242 (20.4) 237 (20.2) 245 (20.9) 250 (21.5) 246 (21.0) 234 (21.2) 234 (22.2) 210 (20.7)
 Late recurrencea 196 (17.0) 213 (18.0) 218 (18.5) 214 (18.3) 195 (16.8) 188 (16.1) 171 (15.5) 162 (15.4) 151 (14.9)
 Second line 682 (28.6) 602 (26.0) 581 (25.5) 567 (25.4) 549 (24.7) 560 (24.5) 555 (24.0) 578 (23.1) 677 (24.5)
 ≥Third line 551 (23.1) 531 (22.9) 519 (22.8) 493 (22.1) 514 (23.1) 554 (24.3) 653 (28.2) 872 (34.8) 1067 (38.7)
  1. Data taken from Ipsos Healthcare Global Oncology Monitor©, January 2012–December 2014. © Ipsos, all rights reserved
  2. aPercentages calculated relative to total patients receiving first-line anti-cancer drug treatment